Table 3.
Sensitivity analysis: the association of thrombocytosis with COPD morbidity using platelet count cutoff of 400 × 109/L
| SPIROMICS | COPDGene | Meta-analysis | |
|---|---|---|---|
| Dichotomous Outcomes [adjusted odds ratio (95% confidence interval)] | |||
| Any Acute Exacerbation of COPD | 1.7 (0.8–3.7) | 1.8 (0.8–3.8) | 1.8 (1.0–3.0) |
| Severe Acute Exacerbation of COPD | 1.6 (0.7–3.8) | 2.7 (1.3–5.8) | 2.2 (1.2–3.8) |
| mMRC Score ≥ 2 | 1.5 (0.7–3.2) | 1.5 (0.6–3.5) | 1.5 (0.9–2.6) |
| CAT Score ≥ 10 | 1.9 (0.6–6.8) | 3.0 (1.0–9.2) | 2.5 (1.1–5.7) |
| GOLD Group D | 2.3 (1.0–5.1) | 2.2 (1.0–4.8) | 2.3 (1.3–3.9) |
| Continuous Outcomes [β (95% confidence interval)] | |||
| Six-minute walk distance (meters) | −12.5 (−53.8, 28.9) | −12.7 (−47.2, 21.7) | −12.6 (−39.1, 13.8) |
| St. George Respiratory Questionnaire score | 5.7 (0.4, 11.1) | 2.1 (−3.5, 7.7) | 4.0 (0.12, 7.8) |
Boldface indicates statistical significance at p < 0.05. mMRC Modified Medical Research Council; CAT COPD Assessment Test